Icon Plc (ICLR) 76.48 $ICLR ICON Completes the
Post# of 273254
Posted On: 09/23/2016 7:18:38 AM
Icon Plc (ICLR) 76.48 $ICLR
ICON Completes the Acquisition of Clinical Research Management, Inc.
BusinessWire - Mon Sep 19, 5:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced acquisition of Clinical Research Management, Inc. (ClinicalRM).
ICLR: 76.48 (+0.59)
How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON
PR Newswire - Fri Jul 29, 7:50AM CDT
The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on Stock-Callers.com are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:
NEO: 8.25 (+0.08), AMAG: 24.16 (+0.10), IDXX: 113.09 (+1.02), ICLR: 76.48 (+0.59)
SmarTrend Watching for Potential Pullback in Shares of ICON After 2.83% Gain
Comtex SmarTrend(R) - Wed Jun 22, 2:18PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $65.14 to a high of $67.47. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $65.88 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ICLR: 76.48 (+0.59)
ICON and Pfizer Extend Ties, Sign New Agreement
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:12AM CDT
ICON Plc (ICLR), recently signed a three-year service agreement with its existing customer Pfizer Inc. (PFE).
AIRM: 33.13 (+1.23), PFE: 34.15 (-0.13), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
New Research from ICON Demonstrates Support for 'Bring Your Own Device' Approach in Clinical Trials
BusinessWire - Wed Jun 15, 2:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical research organisations (CROs) support the use of a 'Bring Your Own Device' (BYOD) approach in clinical studies, enabling patients to use their own mobile devices to collect patient-reported outcomes (PRO) data. The research highlights how commonly-cited concerns around the use of patients' own devices are not as much of a deterrent to adoption as is often thought.
ICLR: 76.48 (+0.59)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE
FE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.
PFE: 34.15 (-0.13), ICLR: 76.48 (+0.59)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Thu Jun 09, 3:20AM CDT
ICON (NASDAQ:ICLR) was downgraded from Market Perform to Underperform at Avondale today. The stock closed yesterday at $69.90 on volume of 407,000 shares, below average daily volume of 447,000. There is potential upside of 14.8% for shares of ICON based on a current price of $69.90 and an average consensus analyst price target of $80.22. The stock should find initial resistance at its 50-day moving average (MA) of $71.69 and further resistance at its 200-day MA of $72.54.
ICLR: 76.48 (+0.59)
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
BusinessWire - Mon May 16, 4:55AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards which took place in Boston on the 27th April.
ICLR: 76.48 (+0.59)
ICON Set to Possibly Rebound After Yesterday's Selloff of 8.53%
Comtex SmarTrend(R) - Tue Apr 26, 3:47PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $66.39 to a high of $72.06. Yesterday, the shares fell 8.5%, which took the trading range below the 3-day low of $71.27 on volume of 706,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ICLR: 76.48 (+0.59)
Icon PLC beats 1Q profit forecasts
Automated Insights - Tue Apr 26, 5:06AM CDT
DUBLIN 18, Ireland (AP) _ Icon PLC (ICLR) on Tuesday reported first-quarter net income of $63 million.
ICLR: 76.48 (+0.59)
ICON Reports First Quarter 2016 Results
BusinessWire - Tue Apr 26, 5:00AM CDT
--Backlog of business up 9% year on year to $3.95 billion
ICLR: 76.48 (+0.59)
ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases
BusinessWire - Tue Feb 09, 4:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.
ICLR: 76.48 (+0.59)
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
ANW: 10.24 (+0.18), HZNP: 19.41 (+0.24), TNP: 5.13 (+0.16), ICLR: 76.48 (+0.59), DAC: 2.95 (+0.12)
5 Smart PIIGS Stocks to Buy Now
Swarup Gupta - Zacks Investment Research - Tue Jan 12, 1:18PM CST
While stocks from Ireland offer a strong economic environment, picks from Greece are available at attractive valuations.
ANW: 10.24 (+0.18), HZNP: 19.41 (+0.24), TNP: 5.13 (+0.16), ICLR: 76.48 (+0.59), DAC: 2.95 (+0.12)
Zacks.com featured expert Kevin Matras highlights: Autobytel, AMN Healthcare Services, Express, Comfort Systems and ICON
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Autobytel, AMN Healthcare Services, Express, Comfort Systems and ICON
FIX: 29.86 (-0.08), EXPR: 11.79 (+0.38), ABTL: 17.08 (+0.26), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
What's Your Stock's Price Target?
Kevin Matras - ZACKS - Tue Jan 05, 2:13PM CST
What's Your Stock's Price Target?
ABTL: 17.08 (+0.26), EXPR: 11.79 (+0.38), FIX: 29.86 (-0.08), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
ICON Completes the Acquisition of Clinical Research Management, Inc.
BusinessWire - Mon Sep 19, 5:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced acquisition of Clinical Research Management, Inc. (ClinicalRM).
ICLR: 76.48 (+0.59)
How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON
PR Newswire - Fri Jul 29, 7:50AM CDT
The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on Stock-Callers.com are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:
NEO: 8.25 (+0.08), AMAG: 24.16 (+0.10), IDXX: 113.09 (+1.02), ICLR: 76.48 (+0.59)
SmarTrend Watching for Potential Pullback in Shares of ICON After 2.83% Gain
Comtex SmarTrend(R) - Wed Jun 22, 2:18PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $65.14 to a high of $67.47. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $65.88 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ICLR: 76.48 (+0.59)
ICON and Pfizer Extend Ties, Sign New Agreement
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:12AM CDT
ICON Plc (ICLR), recently signed a three-year service agreement with its existing customer Pfizer Inc. (PFE).
AIRM: 33.13 (+1.23), PFE: 34.15 (-0.13), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
New Research from ICON Demonstrates Support for 'Bring Your Own Device' Approach in Clinical Trials
BusinessWire - Wed Jun 15, 2:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical research organisations (CROs) support the use of a 'Bring Your Own Device' (BYOD) approach in clinical studies, enabling patients to use their own mobile devices to collect patient-reported outcomes (PRO) data. The research highlights how commonly-cited concerns around the use of patients' own devices are not as much of a deterrent to adoption as is often thought.
ICLR: 76.48 (+0.59)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE
FE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. PFE: 34.15 (-0.13), ICLR: 76.48 (+0.59)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Thu Jun 09, 3:20AM CDT
ICON (NASDAQ:ICLR) was downgraded from Market Perform to Underperform at Avondale today. The stock closed yesterday at $69.90 on volume of 407,000 shares, below average daily volume of 447,000. There is potential upside of 14.8% for shares of ICON based on a current price of $69.90 and an average consensus analyst price target of $80.22. The stock should find initial resistance at its 50-day moving average (MA) of $71.69 and further resistance at its 200-day MA of $72.54.
ICLR: 76.48 (+0.59)
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
BusinessWire - Mon May 16, 4:55AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards which took place in Boston on the 27th April.
ICLR: 76.48 (+0.59)
ICON Set to Possibly Rebound After Yesterday's Selloff of 8.53%
Comtex SmarTrend(R) - Tue Apr 26, 3:47PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $66.39 to a high of $72.06. Yesterday, the shares fell 8.5%, which took the trading range below the 3-day low of $71.27 on volume of 706,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ICLR: 76.48 (+0.59)
Icon PLC beats 1Q profit forecasts
Automated Insights - Tue Apr 26, 5:06AM CDT
DUBLIN 18, Ireland (AP) _ Icon PLC (ICLR) on Tuesday reported first-quarter net income of $63 million.
ICLR: 76.48 (+0.59)
ICON Reports First Quarter 2016 Results
BusinessWire - Tue Apr 26, 5:00AM CDT
--Backlog of business up 9% year on year to $3.95 billion
ICLR: 76.48 (+0.59)
ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases
BusinessWire - Tue Feb 09, 4:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.
ICLR: 76.48 (+0.59)
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
ANW: 10.24 (+0.18), HZNP: 19.41 (+0.24), TNP: 5.13 (+0.16), ICLR: 76.48 (+0.59), DAC: 2.95 (+0.12)
5 Smart PIIGS Stocks to Buy Now
Swarup Gupta - Zacks Investment Research - Tue Jan 12, 1:18PM CST
While stocks from Ireland offer a strong economic environment, picks from Greece are available at attractive valuations.
ANW: 10.24 (+0.18), HZNP: 19.41 (+0.24), TNP: 5.13 (+0.16), ICLR: 76.48 (+0.59), DAC: 2.95 (+0.12)
Zacks.com featured expert Kevin Matras highlights: Autobytel, AMN Healthcare Services, Express, Comfort Systems and ICON
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Autobytel, AMN Healthcare Services, Express, Comfort Systems and ICON
FIX: 29.86 (-0.08), EXPR: 11.79 (+0.38), ABTL: 17.08 (+0.26), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
What's Your Stock's Price Target?
Kevin Matras - ZACKS - Tue Jan 05, 2:13PM CST
What's Your Stock's Price Target?
ABTL: 17.08 (+0.26), EXPR: 11.79 (+0.38), FIX: 29.86 (-0.08), AHS: 34.58 (+0.08), ICLR: 76.48 (+0.59)
(0)
(0)Scroll down for more posts ▼